|
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial |
|
|
|
Title: |
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial |
Author: |
Trněný, Marek Lamy, Thierry Walewski, Jan Belada, David Mayer, Jiri Radford, John Jurczak, Wojciech Morschhauser, Franck Alexeeva, Julia Rule, Simon Afanasyev, Boris Kaplanov, Kamil Thyss, Antoine Kuzmin, Alexej Voloshin, Sergey Kuliczkowski, Kazimierz Giza, Agnieszka Milpied, Noel Stelitano, Caterina Marks, Reinhard Trümper, Lorenz Biyukov, Tsvetan Patturajan, Meera Bravo, Marie-Laure Casadebaig Arcaini, Luca |
Appeared in: |
Lancet oncology |
Paging: |
Volume 17 () nr. 3 pages 319-331 |
Year: |
2016 |
Contents: |
|
Publisher: |
Elsevier Ltd |
Source file: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|